Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Deffered Revenue (2023)

Historic Non-Current Deffered Revenue for Addex Therapeutics (ADXN) over the last 1 years, with Q4 2023 value amounting to $100596.1.

  • Addex Therapeutics' Non-Current Deffered Revenue changed N/A to $100596.1 in Q4 2023 from the same period last year, while for Dec 2023 it was $100596.1, marking a year-over-year change of. This contributed to the annual value of $99354.8 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Addex Therapeutics reported Non-Current Deffered Revenue of $100596.1 as of Q4 2023.
  • Addex Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $100596.1 during Q4 2023, with a 5-year trough of $100596.1 in Q4 2023.